Therapies for Treatment-Resistant Depression

I am Associate Professor with Tenure of Psychiatry and Neuroscience, and Director of the Depression and Anxiety Center for Discovery and Treatment (DAC) at the Icahn School of Medicine at Mount Sinai (ISMMS). My program of research utilizes molecular, neuroimaging, and experimental therapeutics approaches aimed at elucidating the fundamental mechanisms underlying stress-related disorders in humans, including major depressive disorder (MDD), posttraumatic stress disorder (PTSD) and anxiety disorders. The overall goal of my research is to advance the treatment of stress-related disorders through an enhanced understanding of disease pathogenesis and therapeutic mechanisms of action. Dennis S. Charney is an American biological psychiatrist and researcher, with expertise in the neurobiology and treatment of mood and anxiety disorders. He is the author of Neurobiology of Mental Illness, The Physician's Guide to Depression and Bipolar Disorders and Molecular Biology for the Clinician, as well as the author of over 600 original papers and chapters. In 2022, he was listed #52 on Research.com's "Top Medicine Scientists in the United States," with an h-index of 194 with 146,109 citations across 651 publications. Charney is known for demonstrating that ketamine is effective for treating depression. Ketamine's use as a rapidly-acting anti-depressant is recognized as a breakthrough treatment in mental illness.

1. Introduction 2. Treatment-Resistant Depression: Definitions, Epidemiology and Public Health Burden 3. Overview of Current Pharmacotherapy Options and Treatment Algorithms for TRD 4. From Novel Molecules to New Therapeutics for Mood Disorders: Pathways of Drug Discovery 5. Neuroimaging and Brain Based Biomarkers in Treatment-Resistant Depression 6. Inflammation and Peripheral Biomarkers in Treatment-Resistant Depression 7. Role of the Glutamate System in Treatment-Resistant Depression 8. Role of the GABA System in Treatment-Resistant Depression 9. Role of the Neuropeptides and Other Neuro-active Hormones in Treatment-Resistant Depression 10. Ketamine for Treatment-Resistant Depression: Discovery and Current Directions in Research and Clinical Care 11. Safety and Monitoring of Ketamine in Clinical Care 12. Development and Efficacy of Esketamine Treatment-Resistant Depression 13. Novel Glutamate Modulators in Development for Treatment-Resistant Depression 14. Brexanolone and Other GABA Modulators for Treatment-Resistant Depression 15. Special Topics: Psilocybin and Other Psychedelic Agents in Development for TRD 16. Special Topics: Role of Biomakers in Treatment Selection for Treatment-Resistant Depression 17. Special Topics: Current and Future Role of Genetics and Genomics in Treatment-Resistant Depression